We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Cell-Free Bioreactor Produces Therapeutic Proteins for Point-of-Care Use

By LabMedica International staff writers
Posted on 11 Jan 2016
Print article
Image: Section of a serpentine channel reactor shows the parallel reactor and feeder channels separated by a nanoporous membrane. At left is a single nanopore viewed from the side; at right is a diagram of metabolite exchange across the membrane (Photo courtesy of the Oak Ridge [US] National Laboratory).
Image: Section of a serpentine channel reactor shows the parallel reactor and feeder channels separated by a nanoporous membrane. At left is a single nanopore viewed from the side; at right is a diagram of metabolite exchange across the membrane (Photo courtesy of the Oak Ridge [US] National Laboratory).
A microfluidic bioreactor for cell-free protein synthesis was developed to facilitate the production of a single-dose of a therapeutic protein for point-of-care delivery.

Cell-free protein synthesis (CFPS) is the production of protein using biological machinery without the use of living cells. The in vitro protein synthesis environment is not constrained by a cell wall or the homeostasis conditions necessary to maintain a living cell. Thus CFPS enables direct access and control of the translation environment which is advantageous for a number of applications including optimization of protein production, optimization of protein complexes, the study of protein synthesis, incorporating non-natural amino acids, high-throughput screens, and synthetic biology.

Investigators at the Oak Ridge National Laboratory (TN, USA) described in the December 22, 2015, online edition of the journal Small a small footprint device for point-of-care use that comprised a long, serpentine channel bioreactor that was enhanced by integrating a nanofabricated membrane to allow exchange of materials between parallel "reactor" and "feeder" channels. The engineered membrane facilitated the exchange of metabolites, energy, and inhibitory species and could be altered by plasma-enhanced chemical vapor deposition and atomic layer deposition to fine-tune the exchange rate of small molecules.

These design elements enabled extended reaction times and improved yields. Furthermore, the reaction product and higher molecular weight components of the transcription/translation machinery in the reactor channel could be retained.

"With this approach, we can produce more protein faster, making our technology ideal for point-of-care use," said senior author Dr. Scott Retterer, research scientist in the biological and nanoscale systems group at the Oak Ridge National Laboratory. "The fact it is cell-free reduces the infrastructure needed to produce the protein and opens the possibility of creating proteins when and where you need them, bypassing the challenge of keeping the proteins cold during shipment and storage."

Related Links:
Oak Ridge National Laboratory

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.